Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$134.99
1.841.38%
al cierre: -
$134.99
0.000.00%
After hour: 4:00 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Axsome Therapeutics Inc ha un obiettivo di prezzo di consenso pari a $172, stabilito in base alle ultime valutazioni degli analisti di 20. Le ultime 3 valutazioni degli analisti sono state rilasciate da Morgan Stanley, B. Riley Securities y Wells Fargo il octubre 20, 2025, octubre 1, 2025 y septiembre 3, 2025. Con un obiettivo di prezzo medio di $178.67 tra le Morgan Stanley, B. Riley Securities y Wells Fargo, c'è un implicito 32.36% upside per Axsome Therapeutics Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Morgan Stanley
B. Riley Securities
Wells Fargo
UBS
B of A Securities
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Axsome Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/20/2025 | 43.71% | Morgan Stanley | $191 → $194 | Maintains | Overweight | |||
10/01/2025 | 32.6% | B. Riley Securities | → $179 | Initiates | → Buy | |||
09/03/2025 | 20.75% | Wells Fargo | → $163 | Assumes | → Overweight | |||
08/06/2025 | 6.67% | UBS | $133 → $144 | Maintains | Buy | |||
08/05/2025 | 30.38% | B of A Securities | $173 → $176 | Maintains | Buy | |||
08/05/2025 | 40.01% | RBC Capital | $184 → $189 | Maintains | Outperform | |||
08/04/2025 | 11.12% | Needham | $150 → $150 | Reiterates | Buy → Buy | |||
07/03/2025 | 40.75% | Morgan Stanley | → $190 | Assumes | → Overweight | |||
06/12/2025 | 37.79% | RBC Capital | $193 → $186 | Maintains | Outperform | |||
06/10/2025 | 33.34% | HC Wainwright & Co. | $180 → $180 | Reiterates | Buy → Buy | |||
06/09/2025 | 11.12% | Needham | $153 → $150 | Maintains | Buy | |||
06/03/2025 | 37.05% | Oppenheimer | → $185 | Initiates | → Outperform | |||
05/22/2025 | 33.34% | HC Wainwright & Co. | $180 → $180 | Reiterates | Buy → Buy | |||
05/07/2025 | 33.34% | HC Wainwright & Co. | $200 → $180 | Maintains | Buy | |||
05/06/2025 | 22.23% | Wells Fargo | $160 → $165 | Maintains | Overweight | |||
05/06/2025 | 20.01% | Baird | $160 → $162 | Maintains | Outperform | |||
04/29/2025 | 42.97% | RBC Capital | $190 → $193 | Maintains | Outperform | |||
04/07/2025 | 48.16% | Jefferies | → $200 | Initiates | → Buy | |||
04/03/2025 | 48.16% | HC Wainwright & Co. | $200 → $200 | Reiterates | Buy → Buy | |||
04/01/2025 | 13.34% | Needham | $153 → $153 | Reiterates | Buy → Buy | |||
03/27/2025 | 60.01% | Mizuho | $212 → $216 | Maintains | Outperform | |||
03/06/2025 | 48.16% | HC Wainwright & Co. | $200 → $200 | Reiterates | Buy → Buy | |||
03/04/2025 | 40.75% | RBC Capital | $192 → $190 | Maintains | Outperform | |||
03/03/2025 | 13.34% | Needham | $153 → $153 | Reiterates | Buy → Buy | |||
03/03/2025 | 18.53% | Baird | $132 → $160 | Maintains | Outperform | |||
02/27/2025 | 40.75% | Morgan Stanley | $125 → $190 | Maintains | Overweight | |||
02/26/2025 | 57.05% | Mizuho | $195 → $212 | Maintains | Outperform | |||
02/25/2025 | 48.16% | HC Wainwright & Co. | $200 → $200 | Reiterates | Buy → Buy | |||
02/24/2025 | 13.34% | Needham | $153 → $153 | Reiterates | Buy → Buy | |||
02/20/2025 | 48.16% | HC Wainwright & Co. | $190 → $200 | Maintains | Buy | |||
02/19/2025 | 48.16% | Truist Securities | $190 → $200 | Maintains | Buy | |||
02/19/2025 | 42.23% | RBC Capital | $143 → $192 | Maintains | Outperform | |||
02/19/2025 | 13.34% | Cantor Fitzgerald | $153 → $153 | Reiterates | Overweight → Overweight | |||
02/19/2025 | 13.34% | Needham | $133 → $153 | Maintains | Buy | |||
02/12/2025 | 18.53% | Wells Fargo | $140 → $160 | Maintains | Overweight | |||
02/11/2025 | -1.47% | UBS | $105 → $133 | Maintains | Buy | |||
02/11/2025 | 30.38% | Deutsche Bank | → $176 | Initiates | → Buy | |||
02/11/2025 | 23.71% | B of A Securities | $143 → $167 | Maintains | Buy | |||
02/11/2025 | 44.46% | Mizuho | $137 → $195 | Maintains | Outperform | |||
02/11/2025 | 40.75% | HC Wainwright & Co. | $190 → $190 | Reiterates | Buy → Buy | |||
02/10/2025 | 11.12% | Leerink Partners | $110 → $150 | Maintains | Outperform | |||
02/10/2025 | -1.47% | Needham | $133 → $133 | Reiterates | Buy → Buy | |||
02/03/2025 | 1.49% | Mizuho | $122 → $137 | Maintains | Outperform | |||
02/03/2025 | 40.75% | Truist Securities | $180 → $190 | Maintains | Buy | |||
02/03/2025 | 5.93% | RBC Capital | $139 → $143 | Maintains | Outperform | |||
01/31/2025 | 40.75% | HC Wainwright & Co. | $180 → $190 | Maintains | Buy | |||
01/29/2025 | 2.97% | RBC Capital | $139 → $139 | Maintains | Outperform | |||
01/21/2025 | 33.34% | HC Wainwright & Co. | $180 → $180 | Reiterates | Buy → Buy | |||
01/13/2025 | -1.47% | Needham | $133 → $133 | Reiterates | Buy → Buy | |||
01/13/2025 | 33.34% | Truist Securities | $150 → $180 | Maintains | Buy | |||
01/07/2025 | 3.71% | RBC Capital | $138 → $140 | Maintains | Outperform | |||
01/06/2025 | -1.47% | Needham | $133 → $133 | Reiterates | Buy → Buy | |||
12/31/2024 | -9.62% | Mizuho | $124 → $122 | Maintains | Outperform | |||
12/31/2024 | — | HC Wainwright & Co. | — | Reiterates | Buy → Buy | |||
12/30/2024 | -3.7% | Needham | $130 → $130 | Reiterates | Buy → Buy | |||
12/12/2024 | -10.36% | Cantor Fitzgerald | $121 → $121 | Reiterates | Overweight → Overweight | |||
11/27/2024 | 33.34% | HC Wainwright & Co. | $180 → $180 | Reiterates | Buy → Buy | |||
11/25/2024 | 33.34% | HC Wainwright & Co. | $180 → $180 | Reiterates | Buy → Buy | |||
11/13/2024 | -14.07% | Baird | $112 → $116 | Maintains | Outperform | |||
11/13/2024 | -3.7% | Needham | $130 → $130 | Reiterates | Buy → Buy | |||
11/12/2024 | -3.7% | Needham | $130 → $130 | Reiterates | Buy → Buy | |||
10/04/2024 | -2.96% | RBC Capital | $130 → $131 | Maintains | Outperform | |||
09/20/2024 | -20.73% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
09/16/2024 | -20.73% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
09/09/2024 | -20.73% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
09/06/2024 | -20.73% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
09/05/2024 | 33.34% | HC Wainwright & Co. | $180 → $180 | Reiterates | Buy → Buy | |||
09/05/2024 | -3.7% | Needham | $130 → $130 | Reiterates | Buy → Buy | |||
09/03/2024 | 3.71% | Wells Fargo | → $140 | Initiates | → Overweight | |||
08/22/2024 | 33.34% | HC Wainwright & Co. | $180 → $180 | Reiterates | Buy → Buy | |||
08/06/2024 | -22.22% | UBS | $107 → $105 | Maintains | Buy | |||
08/06/2024 | -3.7% | RBC Capital | $131 → $130 | Maintains | Outperform | |||
08/06/2024 | 33.34% | HC Wainwright & Co. | $190 → $180 | Maintains | Buy | |||
08/06/2024 | -21.48% | B of A Securities | $95 → $106 | Upgrade | Neutral → Buy | |||
08/06/2024 | -3.7% | Needham | $130 → $130 | Reiterates | Buy → Buy | |||
08/05/2024 | -3.7% | Needham | $130 → $130 | Reiterates | Buy → Buy | |||
07/26/2024 | -20.73% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
07/22/2024 | -2.96% | RBC Capital | $131 → $131 | Reiterates | Outperform → Outperform | |||
07/22/2024 | -3.7% | Needham | → $130 | Initiates | → Buy | |||
07/18/2024 | -29.62% | B of A Securities | $97 → $95 | Maintains | Neutral | |||
06/12/2024 | -21.48% | Mizuho | $106 → $106 | Reiterates | Buy → Buy | |||
06/06/2024 | 40.75% | HC Wainwright & Co. | $190 → $190 | Reiterates | Buy → Buy | |||
06/05/2024 | -3.7% | RBC Capital | $127 → $130 | Maintains | Outperform | |||
05/08/2024 | -21.48% | Mizuho | $109 → $106 | Maintains | Buy | |||
05/07/2024 | 40.75% | HC Wainwright & Co. | $190 → $190 | Reiterates | Buy → Buy | |||
05/07/2024 | -7.4% | Citigroup | $127 → $125 | Maintains | Buy | |||
05/07/2024 | -17.03% | Baird | $108 → $112 | Maintains | Outperform | |||
04/29/2024 | -14.81% | Morgan Stanley | $90 → $115 | Upgrade | Equal-Weight → Overweight | |||
04/10/2024 | -20.73% | Cantor Fitzgerald | $107 → $107 | Reiterates | Overweight → Overweight | |||
04/02/2024 | 40.75% | HC Wainwright & Co. | $190 → $190 | Maintains | Buy | |||
03/28/2024 | -19.25% | Mizuho | $108 → $109 | Maintains | Buy | |||
03/26/2024 | 11.12% | Truist Securities | → $150 | Maintains | Buy | |||
03/26/2024 | -5.18% | RBC Capital | $123 → $128 | Maintains | Outperform | |||
03/26/2024 | -5.92% | Citigroup | $125 → $127 | Maintains | Buy | |||
03/26/2024 | 40.75% | HC Wainwright & Co. | $180 → $190 | Maintains | Buy | |||
03/20/2024 | 33.34% | HC Wainwright & Co. | $180 → $180 | Reiterates | Buy → Buy | |||
03/19/2024 | -19.99% | Baird | → $108 | Initiates | → Outperform | |||
03/04/2024 | 33.34% | HC Wainwright & Co. | $180 → $180 | Reiterates | Buy → Buy | |||
02/27/2024 | -19.99% | Mizuho | $112 → $108 | Maintains | Buy | |||
02/21/2024 | -20.73% | UBS | $111 → $107 | Maintains | Buy |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Axsome Therapeutics (AXSM)?
El último precio objetivo de Axsome Therapeutics (NASDAQ:AXSM) fue comunicado por Morgan Stanley el octubre 20, 2025. La firma de analistas fijó un precio objetivo para $194.00 que espera AXSM a rise dentro de 12 meses (un posible 43.71% upside). 61 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Axsome Therapeutics (AXSM)?
La última calificación de analistas para Axsome Therapeutics (NASDAQ:AXSM) fue proporcionada por Morgan Stanley, y Axsome Therapeutics mantuvo su overweight calificación.
¿Cuándo se produjo la última revisión al alza de Axsome Therapeutics (AXSM)?
La última revisión al alza de Axsome Therapeutics Inc se produjo en agosto 6, 2024, cuando B of A Securities elevó su precio objetivo a $106. B of A Securities anteriormente tenía a neutral para Axsome Therapeutics Inc.
¿Cuándo fue la última revisión a la baja de Axsome Therapeutics (AXSM)?
No hay una última revisión a la baja para Axsome Therapeutics.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Axsome Therapeutics (AXSM)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Axsome Therapeutics, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Axsome Therapeutics se registró el octubre 20, 2025, por lo que la próxima calificación estará disponible en torno al octubre 20, 2026.
¿Es correcta la calificación de los analistas sobre Axsome Therapeutics (AXSM)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Axsome Therapeutics (AXSM) fue un mantuvo con un precio objetivo de $191.00 a $194.00. El precio actual al que cotiza Axsome Therapeutics (AXSM) es de $134.99, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.